BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 吸入性皮质类固醇(ICS)单一治疗儿童轻度至中度持续性哮喘已被证明对大多数儿童有益。研究哮喘治疗方案的下一步自然是确定ICS的最佳附加药物(增加ICS、LABA或LTRA)，当该剂量的ICS单一治疗不足以令人满意地控制哮喘时。BAGGER，即给予有效反应的最佳附加疗法，将回答180名儿童(每个临床中心36名)的最佳附加药物治疗问题，这些儿童有轻度至中度哮喘病史，且在低剂量ICS治疗下无法完全控制。这项研究的设计是三交叉的，每个孩子都接受每种附加药物的治疗。主要结果将是基于哮喘加重、哮喘控制天数和一秒内用力呼气量变化(肺功能测试)的治疗反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monotherapy with inhaled corticosteroid (ICS) in mild to moderate persistent asthma in children has been shown to be beneficial in most children. The natural next step in studying asthma therapy options is determining the optimal add-on medication (increasing ICS, LABA or LTRA) to ICS when monotherapy with ICS at that dose is inadequate to control asthma satisfactorily. BADGER, or Best Add-on Therapy Giving Effective Responses, will answer the question about best add-on medication in 180 children (36 per clinical center) who have a history of mild to moderate asthma and are not completely controlled on low dose ICS. The study design is a triple cross over with each child receiving each add-on medication. The primary outcomes will be treatment response based on asthma exacerbation, asthma control days, and change in forced expiratory volume in one second (lung function testing).